

中国医药外包年鉴 2010

China Pharma Outsourcing Annual Review 2010



Table of Contents

Scope of the Report

Executive Summary

- ◆ Review of the developments of pharma outsourcing in 2010 in both globe and China;
- ◆ Analysis of major events and activities in 2010 in China pharma outsourcing industry;
- ◆ 2011 Outlook of China pharma outsourcing industry.

Chapter One Review of the Developments of Pharma Outsourcing in 2010 in Both Globe and China

Summary

1.1 Introduction

1.2 Review of global pharma outsourcing development in 2010

- 1.2.1 Review of overall development of global pharma outsourcing in 2010
- 1.2.2 Review of the developments in each service sector of global pharma outsourcing industry in 2010
- 1.2.3 Continued evolving of new outsourcing models pursued by major pharma companies
- 1.2.4 Change of outsourcing demand by global biotech industry

1.3 Review of China pharma outsourcing development in 2010

- 1.3.1 Market growth analysis of Chinese pharma outsourcing industry in 2010
- 1.3.2 Where China currently stands in global pharma outsourcing market: Market growth analysis of global pharma outsourcing industry
- 1.3.3 Current state of Chinese pharma outsourcing industry

Chapter Two Analysis of Major Events and Activities in 2010 in China Pharma Outsourcing Industry

Summary

2.1 Introduction

2.2 Major pharma companies in China in 2010

- 2.2.1 More major pharma companies acquiring Chinese drug companies
 - a. GSK acquired Nanjing MeiRui Pharma
 - b. Sanofi-Aventis acquired BMP Sunstone
 - c. Nycomed acquired Guangdong Techpool Bio-Pharma
 - d. Cardinal Health acquired Zuellig Pharma China
- 2.2.2 Major pharma expanding their R&D and manufacturing facilities in China
 - a. Eli Lilly to establish a dedicated diabetes R&D center in Shanghai
 - b. Takeda acquired the remaining stake in its China JV
 - c. Pfizer opened a new R&D center in Wuhan

- d. Boehringer Ingelheim opened Center of Competence in Shanghai
- e. Roche to increase its China investments and headcounts by 25%
- f. Novo Nordisk to double the size of its Beijing R&D center
- g. Genzyme to jointly establish an R&D center in Tianjin
- h. Merck started construction of pharmaceutical packaging plant in Hangzhou
- i. Merck Serono opened China business division
- j. Sanofi-Aventis opened its expanded R&D center in Shanghai
- 2.2.3 Major pharma conducting clinical trials in China for their new drugs
 - a. Novartis to start first-in-human test of one of its new cancer drugs in China in 2013
- 2.2.4 Major pharma closely collaborating with Chinese organizations
 - a. Bayer Schering to conduct joint research on a biodegradable injection drug delivery system with National Pharmaceutical Engineering Research Center
 - b. Merck signed a mutual intent with Sinopharm to collaborate on HPV and other mutually-selected vaccines in China
 - c. Pfizer seeking research collaborations with organizations in China and other Asian countries
 - d. Johnson Matthey reached an agreement with Aoxing Pharma to produce narcotics and neurological drugs
- 2.2.5 Major pharma licensing drug candidates to Chinese companies
 - a. BMS licensed the rights of its preclinical development candidate to Simcere Pharmaceutical
 - b. Evotec licensed the China development and commercialization rights of one of its drug candidates to Zhejiang Jingxin Pharmaceutical Co., Ltd.
 - c. EnzymeRx licensed a phase I drug to 3SBio
 - d. Isotechnika Pharma licensed next generation calcineurin inhibitor to 3SBio
 - e. ProMetic licensed two drug candidates to Allist
- 2.2.6 Major pharma strengthening their marketing forces and/or launching new drugs in China
- 2.2.7 Major pharma all experiencing fast growth in Chinese pharmaceutical market
- 2.3 Analysis of major events in China pharma outsourcing industry in 2010
 - 2.3.1 Shanghai Medicilon and MPI Research terminated their joint venture in January 2010
 - 2.3.2 The attempted acquisition of WuXi AppTec by Charles River Lab in April 2010
 - 2.3.3 ShangPharma went to IPO at New York Stock Exchange in October 2010
- 2.4 Analysis of major activities of domestic CROs/CMOs in 2010
- 2.5 Analysis of activities of multinational CROs/CMOs in China in 2010
 - a. Icon opened China lab
 - b. PPD opened new China offices
 - c. Quintiles opened new services in Beijing

- d. Parexel opened new offices in China
- e. Kendle's China facility accredited with ISO certificate
- f. i3 acquired ChinaGate Healthcare, Co., Ltd.
- g. SAFC planning to expand in Asia
- h. Evonik opened an API plant in China
- i. Lonza to expand its Nansha site
- j. Thermo expanded its China production facility
- k. DSM formed a JV with Sinochem Group

2.6 Analysis of foreign small biotech companies in China in 2010

Chapter Three 2011 Outlook of China Pharma Outsourcing Industry

Summary

3.1 Outlook of world pharma outsourcing industry in 2011

3.1.1 Analysis of strategies currently implemented by world major pharma companies

3.1.2 Analysis of development trends of major pharma companies outsourcing in China in 2011

3.2 Analysis of development trends of China pharma outsourcing industry in 2011

3.3 Analysis of market growth potentials of Chinese pharma outsourcing industry in 2011

3.4 Analysis of growth obstacles of Chinese pharma outsourcing industry in 2011

Profiled Companies

List of ten profiled companies

About JZMed, Inc.

List of Tables

Table 1. Examples of major pharma companies collaborating with specialty biotech companies to co-develop molecular biomarkers or companion diagnostics

Table 2. Research collaborations between Abbott Lab and other major pharma companies on development of companion diagnostics

Table 3. Growth drivers of strong demand for pharma outsourcing service in China in 2010

Table 4. Unique combination of various resources China currently possesses

Table 5. Current market value and growth history in the past decade of Chinese pharma outsourcing market

Table 6. Market sizes of global pharma outsourcing industry in recent five years

Table 7. Key activities of major pharma companies in Chinese market in 2010

Table 8. Strategies currently implemented by major pharma companies

Table 9. Drug R&D functions that have been mature and can be completely outsourced

Table 10. Areas in which major pharma still collaborating with small biotech companies

Table 11. Common goals of major pharma companies in China (and other Asian

countries)

Table 12. Analysis of current capability of Chinese pharma outsourcing industry

Table 13. 2011 Market development forecast of Chinese pharma outsourcing industry

Table 14. 2011 Market development forecasts of each service sector of Chinese pharma outsourcing industry

List of Figures

Figure 1. Growth trend of Chinese pharma outsourcing market in the past ten years

Figure 2. Past growth trend of global pharma outsourcing market

Figure 3. Market distributions of each service sector in global pharma outsourcing industry

Figure 4. An overview of current state of Chinese pharma outsourcing industry

Figure 5. Forecasted market value of each service sector of Chinese pharma outsourcing industry in 2011

List of Case Studies

Case Study 1. Examples of major CROs restructuring their organization

Case Study 2. Major pharma companies are shrinking the size of their R&D organization and pursuing for more virtual operation model

Case Study 3. WuXi AppTec's service revenue growths in each quarter and entire year of 2010

Case Study 4. ShangPharma's service revenue growths in 2010

Case Study 5. Analysis of major pharma companies licensing early stage drug candidates to Chinese drug companies

Case Study 6. Major pharma companies collaborating with specialty biotech companies

Case Study 7. Major pharma companies showing greater interests in forging partnerships with Asian organizations

Case Study 8. Domestic Chinese drug companies increasingly collaborating with local CROs for drug R&D

Case Study 9. Roche outsourcing clinical trials to local China-based CROs